Stock Taper 
KEY STATISTICS
COMPANY
LEADERSHIP
COMPENSATION 2026
ABOUT
UPCOMING EARNINGS
ETFS HOLDING THIS STOCK
INSTITUTIONAL OWNERSHIP
PRICE
$0.39 ▲ UP 48.35% (+$73.38)No price history available for OABIW over this range.
About OmniAb, Inc.
https://www.omniab.com ↗OmniAb, Inc. provides innovative antibody discovery platforms using genetically engineered transgenic animals to enable the development of next-generation therapeutics and bispecific antibodies.
INDUSTRY
A PRODUCT OMNIAB, INC. IS KNOWN FOR
OmniUltra, OmniAb's advanced platform using engineered chickens, enables novel antibody and peptide discovery to develop next-generation therapeutics like bispecifics, CAR-T, and radioligands targeting challenging biological sites.
OmniAb in 2025
OmniAb Announces $30 Million Private Placement, Causing Significant Stock Price Drop
OmniAb, Inc. announced it had entered into a definitive agreement for a private placement of common stock to raise approximately $30 million. The news of the stock sale and resulting shareholder dilution led to a significant and immediate negative reaction in the company's stock price.
OmniAb Launches Pioneering OmniUltra Platform to Expand into New Therapeutic Areas
OmniAb announced the launch of its OmniUltra™ platform, the industry's first transgenic chicken engineered to produce antibodies with ultralong CDRH3 domains on a human framework. This significant technological advancement expands the company's capabilities beyond conventional antibodies into the peptide space, enabling discovery against challenging therapeutic targets.
RATINGS SNAPSHOT
Overall rating: C
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 VOR | $18.69 | COMPARE |
 OBIO | $5.95 | COMPARE |
 IVVD | $0.82 | COMPARE |
 CGEN | $2.31 | COMPARE |
 CHRS | $1.16 | COMPARE |
 MDWD | $13.52 | COMPARE |
 TARA | $2.70 | COMPARE |
 GNLX | $2.56 | COMPARE |